Johnson & Johnson (NYSE:JNJ) Shares Sold by OLD Point Trust & Financial Services N A

OLD Point Trust & Financial Services N A lessened its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,460 shares of the company’s stock after selling 1,039 shares during the quarter. Johnson & Johnson accounts for about 2.5% of OLD Point Trust & Financial Services N A’s portfolio, making the stock its 14th largest holding. OLD Point Trust & Financial Services N A’s holdings in Johnson & Johnson were worth $7,153,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Northwest & Ethical Investments L.P. grew its position in Johnson & Johnson by 40.7% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 65,024 shares of the company’s stock valued at $9,404,000 after buying an additional 18,794 shares during the period. Symmetry Partners LLC boosted its stake in shares of Johnson & Johnson by 13.2% during the 4th quarter. Symmetry Partners LLC now owns 4,971 shares of the company’s stock worth $719,000 after acquiring an additional 581 shares in the last quarter. Blueshift Asset Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $825,000. iA Global Asset Management Inc. raised its holdings in Johnson & Johnson by 2.6% in the 4th quarter. iA Global Asset Management Inc. now owns 328,245 shares of the company’s stock worth $47,471,000 after purchasing an additional 8,458 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in Johnson & Johnson by 38.2% during the fourth quarter. Teacher Retirement System of Texas now owns 1,008,456 shares of the company’s stock worth $145,843,000 after purchasing an additional 278,913 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Trading Down 0.8 %

Shares of JNJ stock opened at $163.01 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market cap of $392.83 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 2.56 and a beta of 0.47. The company’s 50-day moving average price is $156.15 and its 200-day moving average price is $156.30. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.29 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.